At present, although prostate specific antigen (PSA), PSA density (PSAD), multi-parameter magnetic resonance imaging (mpMRI), prostate specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and other detection methods have played an important role in the diagnosis of PCa, but the gold standard for the diagnosis of PCa is still prostate biopsy (4–6). The gene discussed is FOLH1; the disease is posterior cortical atrophy.